Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.72 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.61 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.60 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.60 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.54 |
| ▸ | TOP1 | P11387 | 8/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738264 | 0.93 | PRKCA (0.83) | PRKCACHEK1DYRK1APAX8PRKCQ | |
| SCHEMBL6729568 | 0.85 | TOP1 (0.62) | PRKCACHEK1DYRK1APAX8TOP1 | |
| SCHEMBL6736494 | 0.85 | PRKCA (0.85) | PRKCACHEK1DYRK1APAX8PRKCQ | |
| SCHEMBL5982059 | 0.84 | PRKCA (0.80) | PRKCATOP1 | |
| SCHEMBL6730339 | 0.84 | PRKCA (0.88) | PRKCADYRK1APAX8PRKCQROCK2 | |
| SCHEMBL12570604 | 0.82 | PRKCA (0.81) | PRKCAPRKCQROCK2TOP1 | |
| SCHEMBL6738330 | 0.82 | PRKCA (0.84) | PRKCADYRK1APAX8PRKCQROCK2 | |
| SCHEMBL29489885 | 0.79 | TOP1 (0.79) | PRKCADYRK1APAX8PRKCQTOP1 | |
| SCHEMBL6729840 | 0.79 | PRKCA (0.55) | PRKCACHEK1DYRK1APAX8PRKCQ | |
| SCHEMBL6736115 | 0.79 | PRKCA (0.78) | PRKCADYRK1APAX8PRKCQTOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242508-A1 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same | LES LABORATOIRES SERVIER (FR) | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242508-A1 | Novel hydroxyalkyl indolocarbazole derivatives, preparation method and pharmaceutical compositions containing the same | RDX, HAX1, HRH1 | PRKCA 3832/4885CHEK1 2331/4885DYRK1A 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.